Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hasane Ratni

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Chimia|September 15, 2021
Contribution to the Discovery of a Novel Medicine for a Neuromuscular Disease and of other Promising Molecules for the Treatment of Neurodevelopmental and Neurodegenerative DiseasesHasane Ratni
Progress in Medicinal Chemistry|March 19, 2019
Rewriting the (tran)script: Application to spinal muscular atrophyHasane Ratni, Lutz Mueller, Martin Ebeling
ACS Medicinal Chemistry Letters|June 18, 2021
Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative MedicinesHasane Ratni, Renata S Scalco, Alexander H Stephan
Journal of Medicinal Chemistry|October 13, 2009
Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structuresPari Malherbe, Claudia Kratzeisen, Anne Marcuz, et al.
Molecular Pharmacology|March 1, 2008
Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domainsPari Malherbe, Caterina Bissantz, Anne Marcuz, et al.
Neuropharmacology|August 10, 2014
Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterizationPari Malherbe, Frédéric Knoflach, Anne Marcuz, et al.
Journal of Medicinal Chemistry|February 6, 2015
Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approachHasane Ratni, Mark Rogers-Evans, Caterina Bissantz, et al.
Nature Chemical Biology|October 23, 2019
Structural basis of a small molecule targeting RNA for a specific splicing correctionSébastien Campagne, Sarah Boigner, Simon Rüdisser, et al.
Journal of Medicinal Chemistry|April 26, 2017
Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular AtrophyEmmanuel Pinard, Luke Green, Michael Reutlinger, et al.
Nature Communications|May 30, 2026
Tunable gene control via RNA splicing with a clinically approved small moleculeMateusz Mendel, Dominic Schwarz, Tao Sun, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Chimia|September 15, 2021
Contribution to the Discovery of a Novel Medicine for a Neuromuscular Disease and of other Promising Molecules for the Treatment of Neurodevelopmental and Neurodegenerative DiseasesHasane Ratni
Progress in Medicinal Chemistry|March 19, 2019
Rewriting the (tran)script: Application to spinal muscular atrophyHasane Ratni, Lutz Mueller, Martin Ebeling
ACS Medicinal Chemistry Letters|June 18, 2021
Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative MedicinesHasane Ratni, Renata S Scalco, Alexander H Stephan
Journal of Medicinal Chemistry|October 13, 2009
Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structuresPari Malherbe, Claudia Kratzeisen, Anne Marcuz, et al.
Molecular Pharmacology|March 1, 2008
Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domainsPari Malherbe, Caterina Bissantz, Anne Marcuz, et al.
Neuropharmacology|August 10, 2014
Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterizationPari Malherbe, Frédéric Knoflach, Anne Marcuz, et al.
Journal of Medicinal Chemistry|February 6, 2015
Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approachHasane Ratni, Mark Rogers-Evans, Caterina Bissantz, et al.
Nature Chemical Biology|October 23, 2019
Structural basis of a small molecule targeting RNA for a specific splicing correctionSébastien Campagne, Sarah Boigner, Simon Rüdisser, et al.
Journal of Medicinal Chemistry|April 26, 2017
Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular AtrophyEmmanuel Pinard, Luke Green, Michael Reutlinger, et al.
Nature Communications|May 30, 2026
Tunable gene control via RNA splicing with a clinically approved small moleculeMateusz Mendel, Dominic Schwarz, Tao Sun, et al.
Pageof 3